Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study

Abstract

Sirukumab had a well-tolerated safety profile, desirable PK characteristics and a low incidence of immunogenicity following an i.v. infusion of 0.3 to 10 mg kg(-1) in healthy subjects.